CAPVAXIVE (V116) is an FDA-approved vaccine for adults to combat invasive pneumococcal disease (IPD). It targets the serotypes responsible for approximately 84% of IPD cases in adults over 50.
Four Phase 3 studies have demonstrated CAPVAXIVE’s strong immune response in non-vaccinated and previously vaccinated adults. This approval adds to Merck’s arsenal of pneumococcal vaccines, offering a focused approach to protect against the predominant IPD-causing serotypes in adults.
CAPVAXIVE’s unique composition includes eight serotypes not covered by other approved pneumococcal vaccines. These serotypes account for a significant portion of IPD cases in adults, particularly those aged 50 and over.
Compared to other available pneumococcal conjugate vaccines, CAPVAXIVE covers a broader range of serotypes responsible for IPD in adults. This enhanced protection is crucial as adult IPD can lead to severe complications, including hospitalization, organ damage, and even death.
The approval of CAPVAXIVE aligns with the CDC’s focus on population-specific vaccines. It provides healthcare professionals with a targeted option to protect adults against the majority of IPD-causing serotypes, offering peace of mind and reducing the risk of severe pneumococcal infections.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
